Latest Global Health News

Island Pharmaceuticals has successfully completed patient dosing in the Phase 2b therapeutic arm of its PROTECT clinical trial for ISLA-101, targeting dengue fever treatment. High-level results are expected within two months, potentially advancing a significant antiviral candidate.

Little Green Pharma has finalized the acquisition of Health House, a key medicinal cannabis distributor, for a fraction of its previous valuation, marking a strategic move to deepen vertical integration.

Argenica Therapeutics has reported compelling preclinical data showing ARG-007 significantly reduces brain cell damage and inflammation in moderate traumatic brain injury, matching levels seen in uninjured controls. This reinforces ARG-007’s potential as a breakthrough neuroprotective therapy.

Optiscan Imaging has initiated a pivotal pre-clinical gastrointestinal study in Germany using its first flexible prototype, aiming to revolutionize real-time GI tract imaging and diagnostics.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

EZZ Life Science Holdings delivered a robust Q2 FY25 with a 16.6% increase in customer receipts and a 308% jump in operating cash flows, while gearing up for US market entry and expanding its global footprint.

Audeara has officially launched its Clinico Sound Earbuds CS1 in Taiwan through a strategic partnership with Clinico Inc., marking a key step in its international expansion and tapping into a growing hearing health market.

Global Health Limited reported a robust 22% increase in customer receipts for the December 2024 quarter, alongside a significant improvement in operating cash flow, positioning the company well amid ongoing healthcare sector challenges.